Microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia: clinical efficacy and mechanisms analysis.

Objective: Microtransplantation (MST) has been found to enhance clinical outcomes in elderly patients with newly diagnosed acute myeloid leukemia (AML) compared with chemotherapy alone. It is important to investigate clinical effectiveness and mechanisms.

Methods: From January 2012 to December 2022, a total of 40 patients over 60 years with newly diagnosed low - and medium-risk AML were analyzed retrospectively, which was divided into two groups: MST group (chemotherapy combined with donor peripheral blood stem cell [PBSC] injection,  = 20) and control group (chemotherapy alone,  = 20).

Genetic analysis should be included in clinical practice when screening for antithrombin deficiency.

Antithrombin (AT) deficiency increases the risk of thrombosis. Current evidence shows that some SERPINC1 mutations responsible for antithrombin deficiency often present a slightly decreased or normal activity and therefore could not be detected by functional tests. This study was designed to compare activity assays and direct genetic analyses in identifying hereditary antithrombin deficiency.

Molecular basis of protein S deficiency in China.

Protein S (ProS) is a physiological inhibitor of coagulation with an important function in the down-regulation of thrombin generation. ProS deficiency is a major risk factor for venous thrombosis. This study enrolled 40 ProS-deficient probands to investigate the molecular basis of hereditary ProS deficiency in Chinese patients.

Common genetic risk factors for venous thrombosis in the Chinese population.

Venous thrombosis is a major medical disorder caused by both genetic and environmental factors. Little is known about the genetic background of venous thrombosis in the Chinese population. A total of 1,304 individuals diagnosed with a first venous thrombosis and 1,334 age- and sex-matched healthy participants were enrolled in this study.